Ovarian hyperstimulation in polycystic ovary syndrome during therapy with leuprolide acetate.
Continuous exposure to GnRH eliminates the pituitary as a source of gonadotropins and may have direct suppressive effects on the ovary. A woman with PCO syndrome received leuprolide acetate (1 mg/d SC) for 4 weeks before and simultaneously with hMG stimulation. Human chorionic gonadotropin (5,000 IU) was administered IM on the 8th day of hMG therapy. There were 10 follicles greater than 15 mm and a polycystic appearance to the ovaries with 25 follicles measuring less than 10 mm. The serum E2 concentration was 2,280 pg/mL. She developed severe ovarian hyperstimulation and required hospitalization for 12 days for fluid management. A viable intrauterine pregnancy was present. Four weeks of pretreatment with leuprolide did not prevent hyperstimulation in the presence of an intrauterine pregnancy.
Walmer
D K
DK
Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710.
Haney
A F
AF
Dodson
W C
WC
D000328:Adult; D000858:Anovulation / Q000188:drug therapy / Q000209:etiology; D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use; D006728:Hormones; D006801:Humans; D016729:Leuprolide; D008596:Menotropins / Q000627:therapeutic use; D010053:Ovary / Q000503:physiopathology*; D010062:Ovulation Induction; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D011247:Pregnancy; D013268:Stimulation, Chemical
D006063:Chorionic Gonadotropin; D006728:Hormones; D007987:Gonadotropin-Releasing Hormone; D008596:Menotropins; D016729:Leuprolide